Relay Therapeutics, Inc. (RLAY)
RLAY moved a median of -0.41% 30 minutes after news, and -0.89% by the close. How RLAY actually reacts to news — the realized, point-in-time move the market made, measured across 335 labeled events over the last three years with zero look-ahead.
RLAY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.09% | 45% | 335 |
| 30-min | -0.41% | 48% | 335 |
| 60-min | -0.22% | 48% | 335 |
| to close | -0.89% | 39% | 334 |
| Middle 50% of RLAY reactions | -1.94% to +1.97% |
|---|---|
| Median reaction (30-min) | -0.41% |
| Measured reactions | 335 |
Half of all Relay Therapeutics, Inc. news events land between -1.94% and +1.97% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RLAY reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 19 | -2.60% | 11% | -2.90% |
| Coverage initiations | 16 | +1.56% | 75% | -0.51% |
| Rating reiterations | 78 | -0.26% | 42% | -0.28% |
| Price-target raises | 18 | -0.13% | 44% | -0.40% |
| Price-target cuts | 15 | 0.00% | 47% | +0.30% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how RLAY ranks against every other measured name →
That’s how RLAY usually reacts — get an email when it moves on news →Email me when RLAY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RLAY's baseline. Nothing else.
Recent RLAY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September | Press release | GlobeNewswire | +2.14% | -1.02% | |
| Form 10-Q Relay Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.78% | +2.86% | |
| Form 8-K Relay Therapeutics, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -0.78% | +2.86% | |
| Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Press release | GlobeNewswire | -0.78% | +2.86% | |
| Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026 | Press release | GlobeNewswire | -1.77% | -4.71% | |
| Form 8-K Relay Therapeutics, Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +1.28% | -3.78% | |
| Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June | Press release | GlobeNewswire | -1.52% | -4.14% | |
| Form 8-K Relay Therapeutics, Inc. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +2.81% | +0.07% | |
| Relay Therapeutics Announces Pricing of Public Offering of Common Stock | Press release | GlobeNewswire | +1.26% | -9.36% | |
| Form 8-K Relay Therapeutics, Inc. For: May 19 | SEC filing · Form 8-K | SEC EDGAR | -9.62% | -7.15% | |
| Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies | Press release | GlobeNewswire | -9.62% | -7.15% | |
| Relay Therapeutics Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | -2.10% | +9.14% | |
| Form 10-Q Relay Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.46% | +1.49% | |
| Form 8-K Relay Therapeutics, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -3.46% | +1.49% | |
| Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates | Press release | GlobeNewswire | -3.46% | +1.49% | |
| Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026 | Press release | GlobeNewswire | -0.23% | +1.09% | |
| Form ARS Relay Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.72% | -4.56% | |
| Form DEF 14A Relay Therapeutics, Inc. For: Jun 09 | SEC filing · Form DEF | SEC EDGAR | -0.72% | -4.56% | |
| Form DEFA14A Relay Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.72% | -4.56% | |
| Form 8-K Relay Therapeutics, Inc. For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.58% | |
| Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer | Press release | GlobeNewswire | +0.00% | -1.58% | |
| Form PRE 14A Relay Therapeutics, Inc. For: Jun 09 | SEC filing · Form PRE | SEC EDGAR | +2.88% | +1.51% | |
| Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 | Press release | GlobeNewswire | +2.81% | -1.43% | |
| Form 8-K Relay Therapeutics, Inc. For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | +2.11% | -2.88% | |
| Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | Press release | GlobeNewswire | +2.11% | -2.88% | |
| Form 8-K Relay Therapeutics, Inc. For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | -2.24% | -1.68% | |
| Form 10-K Relay Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.68% | +6.43% | |
| Form 8-K Relay Therapeutics, Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +3.68% | +6.43% | |
| Form S-8 Relay Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +3.68% | +6.43% | |
| Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones | Press release | GlobeNewswire | +3.68% | +6.43% | |
| Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March | Press release | GlobeNewswire | +2.80% | +0.88% | |
| Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 | Press release | GlobeNewswire | -0.63% | -1.02% | |
| Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | +0.83% | -3.09% | |
| Form 8-K Relay Therapeutics, Inc. For: Feb 03 | SEC filing · Form 8-K | SEC EDGAR | +3.73% | +4.46% | |
| Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer | Press release | GlobeNewswire | +3.73% | +4.46% | |
| Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Press release | GlobeNewswire | -4.06% | -6.63% | |
| Form 10-Q Relay Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.12% | -1.14% | |
| Form 8-K Relay Therapeutics, Inc. For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +2.12% | -1.14% | |
| Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates | Press release | GlobeNewswire | +2.12% | -1.14% | |
| Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November | Press release | GlobeNewswire | +0.29% | +0.88% | |
| Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025 | Press release | GlobeNewswire | -0.14% | -2.59% | |
| Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September | Press release | GlobeNewswire | +0.40% | -3.50% | |
| Form 10-Q Relay Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.57% | +1.26% | |
| Form 8-K Relay Therapeutics, Inc. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +1.57% | +1.26% | |
| Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates | Press release | GlobeNewswire | +1.57% | +1.26% | |
| Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025 | Press release | GlobeNewswire | +0.00% | -3.17% | |
| Form 8-K Relay Therapeutics, Inc. For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | +0.61% | +4.54% | |
| Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors | Press release | GlobeNewswire | +0.61% | +4.54% | |
| Form 8-K Relay Therapeutics, Inc. For: Jun 06 | SEC filing · Form 8-K | SEC EDGAR | -0.87% | -2.33% | |
| Form 8-K Relay Therapeutics, Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -0.93% | +0.31% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RLAY section they belong to.
Where else RLAY is measured.
RLAY earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Relay Therapeutics, Inc.'s median reaction calculated?
Every labeled RLAY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 335 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of RLAY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RLAY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.